NCT06980597View on ClinicalTrials.gov

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathy (IIM)Systemic Sclerosis (SSc)ANCA Associated Vasculitis (AAV)
Interventions
BIOLOGICAL

OL-108

OL-108 will be given through IV bolus with ascending dose levels to determine the maximum tolerated dose (MTD)

Trial Locations (2)

Unknown

RECRUITING

Beijing Boren Hospital, Beijing

RECRUITING

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER